ArticleIrish journal of medical science2022
Breast cancer recurrence: factors impacting occurrence and survival.
Article in Irish journal of medical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer.Breast cancer research : BCR · 2024Pooled it
- Assessing the Role of MicroRNAs in Predicting Breast Cancer Recurrence-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.Breast cancer research : BCR · 2025Trial
- Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.Nature medicine · 2025Trial
- Recurrence in Real Time: Rethinking Breast Cancer Follow-Up Evaluation with Circulating Tumor DNA.Annals of surgical oncology · 2026Article
- Development of ursolic acid-loaded cubosomal nanocarriers: enhanced dissolution, pharmacokinetics, bioavailability, and anticancer activity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Detection of residual fibroglandular tissue on breast MRI and associated factors in women treated with mastectomy and DIEP flap breast reconstruction.Insights into imaging · 2026Article
- Breast Cancer Local Recurrence in Patients With and Without Post-Mastectomy Immediate Breast Reconstruction: Systematic Review and Meta-Analysis.Plastic surgery (Oakville, Ont.) · 2026Review
- Changes in active DNA demethylation pathway components during neoadjuvant chemotherapy and their prognostic significance in breast cancer.Breast cancer research : BCR · 2026Article
- Integrative single-cell and spatial transcriptomics with machine learning identify a Luminal-inflam malignant program and reveal an RPN1-PERK UPR vulnerability in triple-negative breast cancer.Scientific reports · 2026Article
- Incidental discovery of second primary lung tumors in breast cancer patients: an institutional case series.The oncologist · 2026Article
- A distributed fusion framework for breast cancer recurrence prediction using MapReduce.Scientific reports · 2026Article
- Evaluation of Experiences With Ecological Momentary Assessment Among Women With Metastatic Breast Cancer: Qualitative Study.JMIR cancer · 2026Observational
- CDKN1A/p21 Influences the Survival and Expansion of Breast Cancer Stem Cells after Oxidative Damage.Oncology research · 2026Article
- Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.Journal of pharmaceutical policy and practice · 2026Article
- Early recurrence predicts poor post-recurrence survival in young breast cancer patients: development and validation of a prognostic nomogram.American journal of cancer research · 2026Article
- The role of circulating tumor cell-associated genes in the progression of estrogen receptor-positive breast cancer.NPJ breast cancer · 2025Article
- ctDNA detectability and representativeness in seven body liquids from patients with metastatic breast cancer.Nature communications · 2025Article
- Factors Associated With Fear of Cancer Recurrence in a Multiethnic Cohort of Patients With Breast Cancer.Psycho-oncology · 2025Article
- SMOTE-augmented machine learning model predicts recurrent and metastatic breast cancer from microbiome analysis.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer mortality has decreased due to improved screening and treatment options. Nevertheless, 25-30% of patients develop disease recurrence and die from the disease dissemination. Patients who develop metastatic disease represent a heterogeneous group and management plans are dependent on molecular subtype, disease burden and metastatic site.
aimTo determine predictive clinicopathological factors of disease recurrence and their impact on survival in the molecular era.
methodsConsecutive patients who breast cancer developed recurrence at our tertiary referral centre between 2000 and 2015 were included. Clinicopathological and treatment data were assessed using descriptive statistics. Oncological outcome was assessed using Cox regression and Kaplan Meier analyses.
resultsTwo hundred sixty-five consecutive patients who developed breast cancer recurrence were included; median age at metastasis was 59.3 years (range 27-87 years), and median time to recurrence (TTR) was 47.7 ± 38.5 months (range 3.0-194.3 months). Survival was 24.2% (64/265) 53.2% were luminal A (LABC) (141/265), 18.5% were luminal B (LBBC) (49/265), 18.5% were triple negative (TNBC) (49/265), and 9.8% were human epidermal growth factor receptor-2 overexpressing (HER2 +) (26/265). TTR for patients with LABC was 56.0 ± 41.3 months, LBBC was 48.4 ± 41.1 months, TNBC was 26.9 ± 28.5 months and HER2 + was 34.3 ± 21.8 months. Increased grade (P < 0.001), Nottingham Prognostic Indices (P < 0.001), TNBC (P < 0.001), HER2 + subtype (P < 0.001) and receiving targeted therapy (P = 0.006) predicted shorted TTR. Estrogen receptor positivity (P < 0.001), progesterone receptor positivity (P = 0.010), invasive lobular carcinoma (P = 0.009) and receiving endocrine therapy (P = 0.001) predicted longer TTR.
conclusionReadily available clinicopathological factors predict risk of metastatic dissemination. Developing a tailored program to identify patients at risk of recurrence is crucial in controlling metastatic dissemination of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.